Index reshuffle puts Inhibrx Biosciences in the growth spotlight

Inhibrx Biosciences (INBX) is in focus after a broad reshuffle across Russell indices, with the stock leaving several value and defensive benchmarks while joining multiple growth oriented small cap and broad market growth indices.

That reclassification has arrived alongside strong trading momentum in Inhibrx Biosciences, with a 1 day share price return of 3.72%, a 30 day share price return of 15.79% and a 1 year total shareholder return above 4x, suggesting sentiment has shifted toward a higher growth profile.

If you are looking beyond Inhibrx Biosciences for other potential growth stories in healthcare and biotech, it could be worth scanning 40 healthcare AI stocks.

Bulls point to Inhibrx Biosciences’ growth reclassification and strong recent returns, while bears highlight minimal revenue and a sizeable loss. How do the current trading levels stack up against the fundamentals and the expectations being priced in?

DCF focus for Inhibrx Biosciences: when multiples stop helping

For Inhibrx Biosciences, traditional balance sheet based yardsticks are sending mixed signals. The company reports negative shareholders’ equity and a P/B ratio of 70.3x compared with 2.8x for the wider US biotech group and 3.7x for its closer peer set, which makes that multiple hard to use as a clean valuation anchor.

On top of that, there is currently insufficient data to calculate a fair P/B ratio or to run the SWS DCF model for Inhibrx Biosciences, so there is no internal fair value estimate available to compare with the last close of $100.75 or the analyst price target of $277.50.

Those gaps highlight a key point for readers. With negative equity, minimal reported revenue of about $1.3m and ongoing losses of $130.19m, valuation tools that rely on stable book value, earnings or cash flow histories are constrained. As a result, the signals they give around whether the recent re rating is stretched or supported remain incomplete.

Result: Price-to-Book of 70.3x (ABOUT RIGHT)

However, the Inhibrx Biosciences story still carries clear risks, including minimal reported revenue, sizeable losses of $130.19m, and a market cap of about $1.4b.

Next Steps

With sentiment on Inhibrx Biosciences split between concern about risks and optimism about potential rewards, it makes sense to move quickly and check the full picture for yourself. You can start with the 1 key reward and 4 important warning signs.

Looking for more investment ideas beyond Inhibrx Biosciences?

If Inhibrx Biosciences has sharpened your focus on growth and risk, do not stop here. Use targeted screeners to spot other stocks that fit your convictions.

• Target companies with strong income potential by checking out 9 dividend fortresses that could add resilient yield to your portfolio.
• Zero in on potential mispriced opportunities through the screener containing 18 high quality undiscovered gems and get ahead of ideas the market may be overlooking.
• Prioritise capital preservation and steadier performance profiles by reviewing 74 resilient stocks with low risk scores before the next wave of investors arrives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.